欢迎来到 CSNpharm! 产品仅用于科研!
首页 Compound Arrays 促销产品
400-920-2911 sales@csnpharm.cn    

BTK

BTK

货号 产品名 CAS号 信息
CSN22147 Zanubrutinib 1691249-45-2 Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor.
CSN22532 Vecabrutinib 1510829-06-7 Vecabrutinib is a potent BTK inhibitor, with IC50s of 4.6 nM and 1.1 nM for WT BTK and C481S BTK, respectively, and also inhibits ITK activity (IC50, 24 nM).
CSN15892 RN486 1242156-23-5 RN486 is a selective Btk inhibitor with an IC50 Value of 4.0 nM.
CSN13816 QL47 1469988-75-7 QL47 is a potent, selective and irreversible BTK kinase inhibitor with IC50 of 7 nM.
CSN20296 Poseltinib 1353552-97-2 Poseltinib is a tyrosine kinase inhibitor of Bruton's tyrosine kinase (BTK).
CSN20637 PLS-123 1431727-04-6 PLS-123 is a covalent irreversible Btk inhibitor with potential anti-proliferative activity.
CSN24174 PF-06250112 1609465-89-5 PF-06250112 is a potent, highly selective, orally bioavailable BTK inhibitor with an IC50 of 0.5nM, 0.9nM and 1.2nM for BTK, BMX Kinase and TEC, respectively.
CSN18605 PCI-32765 Racemate 936563-87-0 PCI-32765 racemate is a potent and highly selective Btk inhibitor with IC50 of 0.5 nM, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.
CSN13636 Ibrutinib 936563-96-1 PCI-32765 is a potent and highly selective Btk inhibitor with IC50 of 0.5 nM, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.
CSN18219 PCI-29732 330786-25-9 PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay.
CSN27283 Orelabrutinib   1655504-04-3 Orelabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity.
CSN17862 ONO-4059 HCl 1439901-97-9 ONO-4059 is a selective inhibitor of BTK with IC50 2.2 nm, ONO-4059 binds to BTK within B cells, thereby preventing B-cell receptor signaling and impeding B-cell development.
CSN17733 ONO-4059 1351636-18-4 ONO-4059 is a highly selective BTK inhibitor with IC50 of 2.2 nM.
CSN17732 ONO-4059 Analog 1351635-67-0 ONO-4059 Analog is a highly selective BTK inhibitor with IC50 of 2.2 nM.
CSN22302 MT-802 2231744-29-7 MT-802 (MT802) is a potent BTK PROTAC that induces degradation of both wild-type and C481S mutant BTK (DC50=9.1 nM); MT-802 recruits BTK to the cereblon E3 ubiquitin ligase complex to trigger BTK ubiquitination and degradation via the proteasome; MT-802 binds fewer off-target kinases than ibrutinib does and retains an equivalent potency (>99% degradation at nanomolar concentrations) against wild-type and C481S BTK, elicits complete BTK knockdown at 250 nM; reduces the pool of active, phosphorylated BTK in cells isolated from CLL patients with the C481S mutation, whereas ibrutinib cannot.
CSN19154 Ibrutinib-biotin 1599432-18-4 Ibrutinib-biotin is a probe that consists of Ibrutinib linked to biotin via a long chain linker, with an IC50 of 0.755-1.02 nM for BTK.
CSN19159 GDC-0853 1434048-34-6 GDC-0853 is a potent and orally BTK inhibitor.
CSN13839 GDC-0834 S-Enantiomer 1133432-50-4 GDC-0834 S-enantiomer is the S-enantiomer of GDC-0834.
CSN17489 GDC-0834 Racemate 1133432-46-8 GDC-0834 racemate is the racemate form of GDC-0834, which is a potent and selective BTK inhibitor with in vitro IC50s of 5.9 and 6.4 nM in biochemical and cellular assays, respectively.
CSN17490 GDC-0834 1133432-49-1 GDC-0834 is a potent and selective BTK inhibitor with in vitro IC50s of 5.9 and 6.4 nM in biochemical and cellular assays, respectively.
CSN20295 Evobrutinib 1415823-73-2 Evobrutinib is a highly selective inhibitor of the Bruton’s tyrosine kinase (BTK), which is important in the ­development and functioning of various immune cells including B ­lymphocytes and macrophages. Preclinical research suggests it may be therapeutically useful in certain autoimmune diseases.
CSN17176 CNX-774 1202759-32-7 CNX-774 is a potent and selective of Btk with IC50 < 1 nM.
CSN18870 CHMFL-BTK-01 2095280-64-9 CHMFL-BTK-01 is an irreversible BTK inhibitor targeting Cys481 residue while completely abolishing BMX, JAK3 and EGFR's activity.
CSN13815 CGI-1746 910232-84-7 CGI-1746 is a Bruton's tyrosine kinase (Btk) inhibitor.
CSN22295 BTK PROTAC 9 N/A BTK PROTAC 9 is a potent PROTAC for BTK with DC50 of 5.9 nM in cultured Ramos cells, requires simultaneous engagement of BTK and CRBN to effectively degrade BTK; TEC, a closely related protein to BTK that potently binds BTK PROTAC 9 is also degraded.
CSN22294 BTK PROTAC 10 N/A BTK PROTAC 10 is a potent PROTAC for BTK with DC50 of 1.1 nM in cultured Ramos cells; can successfully delivered to tissues and can specifically degrade BTK in vivo, in a dose-dependent and tissue-biased manner by s.c. administration.
CSN25627 BTK inhibitor 4b 1646608-10-7 BTK inhibitor 4b is a highly selective BTK inhibitor with significant efficacy in models in vivo and good ADME and safety profiles.
CSN13705 Btk Inhibitor 1 R-Enantiomer 1022150-12-4 Btk inhibitor 1 R-enantiomer is a Btk kinase inhibitor.
CSN17926 Btk Inhibitor 1 R-Enantiomer HCl 1553977-42-6 Btk inhibitor 1 R-enantiomer HCl is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor.
CSN17811 Btk Inhibitor 1 1412418-47-3 Btk inhibitor 1 is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor.
CSN19157 Btk inhibitor 1 HCl 1807619-60-8 Btk inhibitor 1 HCl is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor.
CSN20297 BMS-986142 1643368-58-4 BMS-986142 is a potent, selective, reversible BTK inhibitor. BMS-986142 shows BTK IC50 = 0.5nM and human WB IC50 = 90 nM.
CSN19767 BMS-935177 1231889-53-4 BMS-935177 is a potent BTK inhibitor with improved kinase selectivity and superior oral exposure in multiple species. should provide useful clinical efficacy in autoimmune diseases.
CSN20168 Zanubrutinib (Recemate) 1633350-06-7 BGB-3111 is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor.
CSN16215 AVL-292 1202757-89-8 AVL-292 is a covalent and highly selective inhibitor of Btk with IC50 of 0.5 nM, exhibiting > 1400-fold selectivity over the other kinases assayed.
CSN17749 AVL-292 Benzenesulfonate 1360053-81-1 AVL-292 benzenesulfonate is a potent inhibitor of Btk kinase activity (IC50< 0.5 nM, Kinact/Ki=7.69×104 M-1s-1s) in biochemical assays.
CSN21093 ARQ 531 2095393-15-8 ARQ-531 is a potent and orally active BTK inhibitor with potential antineoplastic activity.
CSN16252 Acalabrutinib 1420477-60-6 Acalabrutinib is a second-generation, selective and irreversible inhibitor of BTK (Bruton's tyrosine kinase) with an IC50 of 3 nM and EC50 of 8 nM in a human whole-blood CD69 B cell activation assay. Acalabrutinib has improved pharmacologic features, including favorable plasma exposure, rapid oral absorption, a short half-life, and the absence of irreversible targeting to alternative kinases.
CSN22895 (-)-Terreic Acid 121-40-4 (-)-Terreic Acid is a selective inhibitor of Bruton's tyrosine kinase (BTK).
<< PREV 1 2 NEXT >>